<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">AAPS J</journal-id><journal-id journal-id-type="pmc-domain-id">792</journal-id><journal-id journal-id-type="pmc-domain">aapsj</journal-id><journal-title-group><journal-title xml:lang="en">The AAPS Journal</journal-title></journal-title-group><issn pub-type="epub">1550-7416</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2750978</article-id><article-id pub-id-type="pmcid-ver">PMC2750978.1</article-id><article-id pub-id-type="pmcaid">2750978</article-id><article-id pub-id-type="pmcaiid">2750978</article-id><article-id pub-id-type="pmid">16353920</article-id><article-id pub-id-type="doi">10.1208/aapsj070241</article-id><article-id pub-id-type="publisher-id">72408</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A pragmatic approach to the design of population pharmacokinetic studies</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Roy</surname><given-names initials="A">Amit</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ette</surname><given-names initials="EI">Ene I.</given-names></name><address><phone>(617) 444-6318</phone><fax>(617) 444-6713</fax><email>ene_ette@vrtx.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Strategic Modeling and Simulation, Bristol-Myers Squibb, 08543 Princeton, NJ </aff><aff id="Aff2"><label>2</label>Department of Clinical Pharmacology, Vertex Pharmaceuticals, 130 Waverly St., 02139 Cambridge, MA </aff></contrib-group><pub-date pub-type="collection"><month>6</month><year>2005</year></pub-date><pub-date pub-type="epub"><day>5</day><month>10</month><year>2005</year></pub-date><volume>7</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">181858</issue-id><fpage>E408</fpage><lpage>E420</lpage><history><date date-type="received"><day>11</day><month>5</month><year>2005</year></date><date date-type="accepted"><day>11</day><month>5</month><year>2005</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>10</month><year>2006</year></date></event><event event-type="pmc-live"><date><day>14</day><month>10</month><year>2009</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2014-07-09 00:20:14.180"><day>09</day><month>07</month><year>2014</year></date></event></pub-history><permissions><copyright-statement>&#169; American Association of Pharmaceutical Scientists 2005</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12248_2008_Article_72408.pdf"/><abstract xml:lang="en"><p>The publication of a seminal article on nonlinear mixed-effect modeling led to a revolution in pharmacokinetics (PKs) with the introduction of the population approach. Since then, interest in obtaining accurate and precise estimates of population PK parameters has led to work on population PK study design that extended previous work on optimal sampling designs for individual PK parameter estimation. The issues and developments in the design of population PK studies are reviewed as a prelude to investigating, via simulation, the performance of 2 approaches (population Fisher information matrix D-optimal design and informative block [profile] randomized [IBR] design) for designing population PK studies. The results of our simulation study indicate that the designs based on the 2 approaches yielded efficient parameter estimates. The designs based on the 2 approaches performed similarly, and in some cases designs based on the IBR approach were slightly better. The ease with which the IBR designs can be generated makes them preferable in drug development, where pragmatism and time are of great consideration. We, therefore, refer to the IBR designs as pragmatic designs. Pragmatic designs that achieve high efficiency in the estimation parameters should be used in the design of population PK studies, and simulation should be used to determine the efficiency of the designs.</p></abstract><kwd-group><title>Keywords</title><kwd>population pharmacokinetic sampling design</kwd><kwd>D-optimality</kwd><kwd>informative block randomized design</kwd><kwd>population Fisher information matrix D-optimal design</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; American Association of Pharmaceutical Scientists 2005</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>